NASDAQ:CDAK

Codiak BioSciences (CDAK) Stock Forecast, Price & News

$0.0090

0.00 (0.00%)

(As of 06/7/2023 ET)

Compare

Today's Range: $0.0090
▼
$0.0146
50-Day Range: $0.01
▼
$0.19
52-Week Range: $0.05
▼
$6.98

Volume: 607,991 shs
Average Volume: 1.37 million shs
Market Capitalization: $331,470.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.20

Codiak BioSciences MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 46,566.7% Upside
$4.20 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.57
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$7,826 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Codiak BioSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.20, Codiak BioSciences has a forecasted upside of 46,566.7% from its current price of $0.01.
Amount of Analyst Coverage
Codiak BioSciences has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for CDAK.

0.0

Dividend Strength

Dividend Yield
Codiak BioSciences does not currently pay a dividend.
Dividend Growth
Codiak BioSciences does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Codiak BioSciences has received a 76.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Codiak BioSciences is -0.57.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Codiak BioSciences this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Codiak BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Codiak BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,826.00 in company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Codiak BioSciences is held by insiders.
Percentage Held by Institutions
71.30% of the stock of Codiak BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Codiak BioSciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Codiak BioSciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Codiak BioSciences has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Codiak BioSciences (NASDAQ:CDAK) Stock

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive CDAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CDAK Stock News Headlines

June 2, 2023 | americanbankingnews.com

Financial Review: Entera Bio (NASDAQ:ENTX) versus Codiak BioSciences (NASDAQ:CDAK)

May 31, 2023 | americanbankingnews.com

Head to Head Analysis: Codiak BioSciences (NASDAQ:CDAK) vs. BioNTech (NASDAQ:BNTX)

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 19, 2023 | finance.yahoo.com

Mariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial Officer

May 18, 2023 | americanbankingnews.com

Comparing Century Therapeutics (NASDAQ:IPSC) & Codiak BioSciences (NASDAQ:CDAK)

April 15, 2023 | reuters.com

CDAK.O

April 2, 2023 | benzinga.com

How Does Codiak BioSciences Inc (CDAK) Stock Rank on Wall Street Friday?

March 27, 2023 | finance.yahoo.com

Codiak BioSciences Files For Chapter 11 Bankruptcy

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

March 27, 2023 | marketwatch.com

Codiak BioSciences Shares Hit 52-Week Low After Bankruptcy Filing

March 27, 2023 | bizjournals.com

Struggling MD Anderson spinout files for bankruptcy protection

March 27, 2023 | finanznachrichten.de

Codiak BioSciences, Inc.: Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

March 27, 2023 | benzinga.com

Codiak BioSciences shares are trading lower after the company voluntarily filed for protection under Chapter 11 bankruptcy.

March 27, 2023 | reuters.com

COVID vaccine developer Codiak files for US bankruptcy protection

March 27, 2023 | msn.com

Codiak Bio Tumbles on Bankruptcy Filing

March 27, 2023 | markets.businessinsider.com

Codiak BioSciences Voluntarily Files For Bankruptcy Protection

March 27, 2023 | finance.yahoo.com

Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

March 22, 2023 | seekingalpha.com

CDAK Codiak BioSciences, Inc.

March 3, 2023 | msn.com

Laurion Capital Management Now Owns 9.60% of Codiak BioSciences (CDAK)

February 21, 2023 | bizjournals.com

Blood disorder startup Hemab Therapeutics raises $135M

November 28, 2022 | finance.yahoo.com

Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

November 10, 2022 | finance.yahoo.com

Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

November 9, 2022 | finance.yahoo.com

Codiak BioSciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

November 4, 2022 | finance.yahoo.com

Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates

November 3, 2022 | technews.tmcnet.com

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

November 3, 2022 | finance.yahoo.com

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

October 19, 2022 | finance.yahoo.com

All You Need to Know About Codiak BioSciences, Inc. (CDAK) Rating Upgrade to Strong Buy

See More Headlines

CDAK Price History

30 days | 90 days | 365 days | Advanced Chart

CDAK Company Calendar

Last Earnings: 11/04/2021
Today: 6/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CDAK
CUSIP: N/A
CIK: 1659352
Web: www.codiakbio.com
Phone: 617-949-4100
Fax: N/A
Employees: 102
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.20
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $1.40
Forecasted Upside/Downside: +46,566.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,160,000.00
Net Margins: -51.13%
Pretax Margin: -51.13%
Return on Equity: -109.51%
Return on Assets: -34.44%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 4.24
Quick Ratio: 4.24

Sales & Book Value

Annual Sales: $33.57 million
Price / Sales: 0.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.39 per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 36,830,000
Free Float: 33,810,000
Market Cap: $331,470.00
Optionable: Not Optionable
Beta: 3.71

Key Executives

Dr. Douglas Edward Williams Ph.D. (Age 64)
Pres, CEO & Director
Comp: $970.77k

Ms. Linda Cathavina Bain CPA (Age 52)
CFO & Treasurer
Comp: $602.54k

Dr. Sriram Sathyanarayanan Ph.D. (Age 50)
Chief Scientific Officer
Comp: $502.17k

Dr. Konstantin Konstantinov Ph.D. (Age 64)
Chief Technology Officer

Mr. Christopher J. M. Taylor
VP of Investor Relations & Corp. Communications

Ms. Yalonda Howze (Age 50)
Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec.

Ms. Nicole Barna (Age 48)
Sr. VP of HR

Dr. David J. Mauro M.D. (Age 57)
Ph.D., Chief Medical Officer

Dr. Benny Sorensen M.D. (Age 48)
Ph.D., Member of Scientific Advisory Board & Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDAK Stock - Frequently Asked Questions

Should I buy or sell Codiak BioSciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codiak BioSciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CDAK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDAK, but not buy additional shares or sell existing shares.
View CDAK analyst ratings or view top-rated stocks.
What is Codiak BioSciences' stock price forecast for 2023?: 1 Wall Street research analysts have issued 1 year price targets for Codiak BioSciences' shares. Their CDAK share price forecasts range from $1.40 to $7.00. On average, they anticipate the company's share price to reach $4.20 in the next year. This suggests a possible upside of 46,566.7% from the stock's current price.
View analysts price targets for CDAK or view top-rated stocks among Wall Street analysts.
How have CDAK shares performed in 2023?: Codiak BioSciences' stock was trading at $0.3976 at the start of the year. Since then, CDAK shares have decreased by 97.7% and is now trading at $0.0090.
View the best growth stocks for 2023 here.
How were Codiak BioSciences' earnings last quarter?: Codiak BioSciences, Inc. (NASDAQ:CDAK) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.12. The firm earned $1.16 million during the quarter, compared to analysts' expectations of $2.87 million. Codiak BioSciences had a negative trailing twelve-month return on equity of 109.51% and a negative net margin of 51.13%.
When did Codiak BioSciences IPO?: (CDAK) raised $82 million in an IPO on Wednesday, October 14th 2020. The company issued 5,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow served as the underwriters for the IPO.
What is Codiak BioSciences' stock symbol?: Codiak BioSciences trades on the NASDAQ under the ticker symbol "CDAK."

Who are Codiak BioSciences' major shareholders?: Codiak BioSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Benny Sorensen, Briggs Morrison, Douglas E Williams, Konstantin Konstantinov, Linda Bain, Nicole Barna, Sriram Sathyanarayanan, Venture Fund Viii LP Arch and Yalonda Howze.
View institutional ownership trends.
How do I buy shares of Codiak BioSciences?: Shares of CDAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Codiak BioSciences' stock price today?: One share of CDAK stock can currently be purchased for approximately $0.01.
How much money does Codiak BioSciences make?: Codiak BioSciences (NASDAQ:CDAK) has a market capitalization of $331,470.00 and generates $33.57 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.
How many employees does Codiak BioSciences have?: The company employs 102 workers across the globe.
How can I contact Codiak BioSciences?: The official website for the company is www.codiakbio.com. The company can be reached via phone at 617-949-4100 or via email at investorrelations@codiakbio.com.

This page (NASDAQ:CDAK) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Codiak BioSciences (CDAK) Stock Forecast, Price & News

Codiak BioSciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Codiak BioSciences (NASDAQ:CDAK) Stock

CDAK Stock News Headlines

CDAK Price History

CDAK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CDAK Stock - Frequently Asked Questions

Overall MarketRank^™